Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

Throughout her career, One2Treat’s Émilie Barré has focused on developing both the analytical and leadership aspects ...

Manas AI secures funding led by General Catalyst to scale AI-driven drug discovery, tackling cancer and rare diseases.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Arctic Therapeutics announced this week that it has raised €26.5 million, a sum bankrolled by investors including the European Innovation Council (EIC) Fund, the Icelandic investment firm Kaldbakur ...

From Novo Holding’s purchase of Catalent to BMS’s Karuna acquisition, here are 10 of the most significant M&A moments last year Compared to the previous years, 2024 has been a relatively slow year for ...

Australian contract development and manufacturing organizations (CDMOs), BioCina and NovaCina, have merged in a move to pool their biologic and small molecule production expertise and infrastructure.

Results from the STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for. Novo Nordisk has announced topline results from the ...

We ran a Q&A with John Clarke, associate director in patient recruitment at Innovaderm on the changing landscape of patient centricity in terms of clinical trials and how the industry can navigate the ...

We ran a Q&A With Michael Young, co-founder of Lindus Health on the challenges of 2024 and the company’s goals for 2025 What are the most significant milestones your company achieved in 2024, and how ...